Apar Kishor Ganti, MD
Hematology & Oncology · Omaha, NENPI 1124076997
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $115,080 of the $138,253 with a category attached, or 83.2%. 16 manufacturers reported payments, led by AstraZeneca at 47.8% of the total. Among hematology & oncology clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 91 payments — averaging $1519.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$66K
- Jazz Pharmaceuticals Inc.$49K
- Pfizer$5K
- Sanofi$3K
- Regeneron$3K
- Blueprint Medicines Corporation$3K
- plus $10K from 10 others
Across 91 payments — averaging $9198.93 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$629K
- Novartis$113K
- Iovance Biotherapeutics, Inc.$59K
- AstraZeneca$13K
- Mirati Therapeutics, Inc.$11K
- Boehringer Ingelheim International GmbH$5K
- plus $6K from 2 others
What the payments were for
- Consulting fees$115,08083%
- Speaking & faculty fees$19,56114%
- Travel & lodging$1,8111%
- Food & beverage$1,7811%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 44 | $66,048 |
| Jazz Pharmaceuticals Inc. | 26 | $48,959 |
| Pfizer | 2 | $5,140 |
| Sanofi | 1 | $2,916 |
| Regeneron | 2 | $2,902 |
| Blueprint Medicines Corporation | 1 | $2,599 |
| Merck | 2 | $2,580 |
| Eisai Inc. | 1 | $2,040 |
| Beigene, Ltd. | 1 | $1,441 |
| Catalyst Pharmaceuticals, Inc. | 2 | $1,149 |
| Bayer | 1 | $1,028 |
| Amgen | 2 | $974 |
| Galvanize Therapeutics, Inc | 1 | $171 |
| Genentech USA, Inc. | 2 | $168 |
| Fosun Pharma USA Inc. | 2 | $105 |
| Dendreon Pharmaceuticals LLC | 1 | $36 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$138,253 in reported general payments places this provider in the 95th percentile of 73 hematology & oncology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 82 | $1,237,867 |
| LenvimaLenvatinib Mesylate | 23 | $510,971 |
| RetevmoSelpercatinib | 11 | $261,225 |
| VotrientPazopanib Hcl | 13 | $106,130 |
| EliquisApixaban | 19 | $15,948 |
| Ondansetron Hcl | 60 | $789 |
| Dexamethasone | 41 | $549 |
| Doxycycline Monohydrate | 14 | $434 |
| Prochlorperazine Maleate | 37 | $428 |
| Levothyroxine Sodium | 52 | $345 |
| Oxycodone Hcl | 12 | $187 |
| Prednisone | 23 | $74 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso | $66,048 | $1,237,86782 claims |
| Eisai Inc.Lenvima | $2,040 | $510,97123 claims |
| PfizerEliquis | $5,140 | $15,94819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 73 hematology & oncology providers in Nebraska.
Other hematology & oncology in Omaha
- Mojtaba AkhtariOmaha$1.8M
- Luke NordquistOmaha$202K
- Julie VoseOmaha$123K
- Peter SilbersteinOmaha$99K
- Krishna GundaboluOmaha$76K
- Vijaya BhattOmaha$58K
- Samer RennoOmaha$41K
- Timothy DoriusOmaha$24K
- Stefano TarantoloOmaha$13K
- Marcel DevettenOmaha$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.